Idera Pharmaceuticals Q2 EPS $(0.15) Up From $(0.24) YoY

Idera Pharmaceuticals (NASDAQ:IDRA) reported quarterly losses of $(0.15) per share. This is a 37.5 percent increase over losses of $(0.24) per share from the same period last year.

byBill Haddad

August 9, 2021

1 minute read

Idera Pharmaceuticals (NASDAQ:IDRA) reported quarterly losses of $(0.15) per share. This is a 37.5 percent increase over losses of $(0.24) per share from the same period last year.

Atara Biotherapeutics And Pierre Fabre Enter Strategic Collaboration To Commercialize Tabelecleucel; Atara To Receive Upfront Payment Of $45M, And Up To ~$320M In Total Milestones

By Benzinga Newsdesk

Today, 6:56 AM

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for

ATRA

Psychedelics Firm Eleusis Goes Public Via Merger With Silver Spike Acquisition Creating $450M Company

By Nina Zdinjak

Today, 6:56 AM

British psychedelics company Eleusis will go public via a merger with Silver Spike Acquisition Corp. II (“SPKB”) (NASDAQ: SPKB), a special purpose acquisition company sponsored by an affiliate of Silver Spike Capital.

SPKB